oa Response to ‘Lack of reversibility for NOACs’

References

1. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013; 34:27:2094–2106.
   [Google الباحث العلمي]
2. van Ryn J, Litzenburger T, Gan G, Coble K, Schurer J. In Vitro Characterization, Pharmacokinetics and Reversal of Supratherapeutic Doses of Dabigatran-Induced Bleeding in Rats by a Specific Antibody Fragment Antidote to Dabigatran. Stroke. 2013; 44::AWP261.
   [Google الباحث العلمي]